180 related articles for article (PubMed ID: 12165065)
1. Safety pharmacology and risk assessment.
Kinter LB; Valentin JP
Fundam Clin Pharmacol; 2002 Jun; 16(3):175-82. PubMed ID: 12165065
[TBL] [Abstract][Full Text] [Related]
2. Origins, practices and future of safety pharmacology.
Bass A; Kinter L; Williams P
J Pharmacol Toxicol Methods; 2004; 49(3):145-51. PubMed ID: 15172010
[TBL] [Abstract][Full Text] [Related]
3. Safety pharmacology--a progressive approach.
Redfern WS; Wakefield ID; Prior H; Pollard CE; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2002 Jun; 16(3):161-73. PubMed ID: 12165064
[TBL] [Abstract][Full Text] [Related]
4. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.
Authier S; Pugsley MK; Troncy E; Curtis MJ
J Pharmacol Toxicol Methods; 2010; 62(2):83-8. PubMed ID: 20601020
[TBL] [Abstract][Full Text] [Related]
5. The application of in vitro methods to safety pharmacology.
Wakefield ID; Pollard C; Redfern WS; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2002 Jun; 16(3):209-18. PubMed ID: 12165068
[TBL] [Abstract][Full Text] [Related]
6. Quality management of pharmacology and safety pharmacology studies.
Spindler P; Seiler JP
Fundam Clin Pharmacol; 2002 Apr; 16(2):83-90. PubMed ID: 12031061
[TBL] [Abstract][Full Text] [Related]
7. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
8. Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology.
Chain AS; Sturkenboom MC; Danhof M; Della Pasqua OE
Drug Discov Today Technol; 2013 Sep; 10(3):e373-83. PubMed ID: 24050134
[TBL] [Abstract][Full Text] [Related]
9. Safety pharmacology in the nonclinical assessment of new medicinal products: definition, place, interest and difficulties.
Claude JR
Fundam Clin Pharmacol; 2002 Apr; 16(2):75-8. PubMed ID: 12031059
[TBL] [Abstract][Full Text] [Related]
10. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
[TBL] [Abstract][Full Text] [Related]
11. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
Cavero I
Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
[TBL] [Abstract][Full Text] [Related]
12. Assessment of respiratory function in safety pharmacology.
Murphy DJ
Fundam Clin Pharmacol; 2002 Jun; 16(3):183-96. PubMed ID: 12165066
[No Abstract] [Full Text] [Related]
13. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
Shah RR
Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
[TBL] [Abstract][Full Text] [Related]
14. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
[TBL] [Abstract][Full Text] [Related]
15. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
16. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.
Picard S; Goineau S; Guillaume P; Henry J; Hanouz JL; Rouet R
Cardiovasc Toxicol; 2011 Dec; 11(4):285-307. PubMed ID: 21805209
[TBL] [Abstract][Full Text] [Related]
17. GLP in safety pharmacology studies: Report card after 15years.
Guth BD; Pugsley MK
J Pharmacol Toxicol Methods; 2017 Sep; 87():24-26. PubMed ID: 28192184
[No Abstract] [Full Text] [Related]
18. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
19. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
[TBL] [Abstract][Full Text] [Related]
20. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
De Clerck F; Van de Water A; D'Aubioul J; Lu HR; van Rossem K; Hermans A; Van Ammel K
Fundam Clin Pharmacol; 2002 Apr; 16(2):125-40. PubMed ID: 12031065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
